Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab

BACKGROUND Hyperhemolysis syndrome (HHS) is a posttransfusion complication most frequently seen in sickle cell disease (SCD), characterized by rapid destruction of transfused and autologous red blood cells (RBCs), resulting in reticulocytopenia and a decrease in hemoglobin to below pretransfusion le...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transfusion (Philadelphia, Pa.) Pa.), 2020-01, Vol.60 (1), p.30-35
Hauptverfasser:	Lee, Lauren E., Beeler, Bradley W., Graham, Brendan C., Cap, Andrew P., Win, Nay, Chen, Frederick
Format:	Artikel
Sprache:	eng
Schlagworte:	Alloantibodies Anemia Case reports Cell activation Coombs' test Destruction Erythrocytes Ferritin Globulins Hemoglobin Hypoxemia Immunoglobulins Immunosuppressive agents Interleukins Intravenous administration Macrophages Monoclonal antibodies Reticulocytopenia Sickle cell disease Steroid hormones Steroids Therapy Transfusion
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!